Implementing an intra outbreak ring vaccination clinical trial for Sudan Ebola virus disease within four days of outbreak notification in Uganda.

Authors

Winters Muttamba, Henry Kyobe Bosa, Misaki Wayengera, Andrew Obuku, Maria Sekimpi, Geofrey Kimbugwe, Wilber Sabiiti, Pauline Byakika-Kibwika, Noah Kiwanuka, Rebecca Nantanda, Diana Atwine, Charles Olaro, Diallo Abdourahamane, Alhassane Toure, Ana Maria Henao-Restrepo, Pontiano Kaleebu, Bruce Kirenga

Published in

Emerging microbes & infections. Pages 2731496. Sep 07, 2026. Epub Sep 07, 2026.

Abstract

East and Central Africa experiences heightened threats for Ebola Virus Disease (EVD), with the latest outbreak caused by the Bundibugyo ebolavirus (BDBV) reported in the Democratic Republic of the Congo (DRC) and Uganda on 15^th May 2026. The BDBV outbreak comes just over a year following declaration of Sudan Virus Disease (SVD) outbreak in Uganda on 30^th January 2025. Following the 2025 outbreak, a race against the clock mobilisation occurred over the subsequent four days to launch a ring vaccination trial for a candidate vaccine against SVD. During this four-day period, the investigation team leveraged ongoing engagements with trial sponsors to activate prefinancing mechanisms and unlock in-kind financing from the government of Uganda. Further, the team activated a prepositioned research protocol to secure rapid ethics and regulatory clearance, and quickly accessed investigation product within the country, supportive ethics/regulatory systems, presence of logistical and data management systems established during the 2022 outbreak, collaborative relationship between the trial and the Ministry of Health outbreak response teams. Finally, previously trained field and community engagement personnel were mobilised overnight, offered refresher training and rapidly deployed to the field. In conclusion, the unprecedented four-day turnaround was made possible by the research, logistical and staffing capacities established during the 2022 SVD outbreak, an achievement that offers a blueprint for rapid evaluation of medical countermeasures during outbreaks.

PMID:
42703692
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.